Docetaxel in Non Small Cell Lung Cancer (NSCLC)
NCT00258739
·
clinicaltrials.gov ↗
PHASE2
Phase
COMPLETED
Status
140
Enrollment
INDUSTRY
Sponsor class
Conditions
Lung Neoplasms
Interventions
DRUG:
Docetaxel + carboplatin + radiotherapy + docetaxel + gemcitabine
OTHER:
Docetaxel + gemcitabine + carboplatin + radiotherapy
Sponsor
Sanofi